BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Niceritrol

An ester of nicotinic acid that lowers cholesterol and triglycerides in total plasma and in the VLD- and LD-lipoprotein fractions.

53+ PubMed studies analyzed · 5 RCTs · Evidence Score: 46

Research Domains

Niceritrol has been studied across 12 research domains including 🔥 Metabolic, ❤️ Cardiovascular, 🫘 Kidney, 😴 Sleep, 🫁 Liver & Detox. The primary research focus is 🔥 Metabolic with 79% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Niceritrol, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Moricizine
3 shared targets
limonin
3 shared targets
Nandrolone
3 shared targets
Doripenem
3 shared targets
Anastrozole
3 shared targets
Pinacidil
2 shared targets
Dexamethasone
3 shared targets
pivampicillin
3 shared targets
Mephenesin
2 shared targets
Torsemide
3 shared targets
Loading evidence profile...

This evidence profile for Niceritrol is generated deterministically from 53 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.